Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 13Thoracic 2Dermatologic 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 50Colorectal Neoplasms 39Stomach Neoplasms 27Carcinoma, Hepatocellular 26Ovarian Neoplasms 25Melanoma 21Breast Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Neoplasms 15Neoplasm Metastasis 15Colonic Neoplasms 14Esophageal Neoplasms 13Uterine Cervical Neoplasms 11Sarcoma 10Liver Neoplasms 10Carcinoma, Renal Cell 10Lung Neoplasms 9Anus Neoplasms 9Rectal Neoplasms 8Head and Neck Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Osteosarcoma 7Triple Negative Breast Neoplasms 6Mesothelioma 6Hepatoblastoma 6Gastrointestinal Neoplasms 6Carcinoma 6Adenocarcinoma 6Vaginal Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

pembrolizumab 1Radiation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma, Myxoid × Cyclophosphamide × Gastrointestinal × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡